HistoSonics Raises $85M for Edison Histotripsy Platform

HistoSonics, developer of a non-invasive sonic beam therapy, has raised $85 million in a financing round led by Johnson & Johnson Innovation (JJDC Inc.) The company also concurrently obtained commitment for a $15 million expansion of the amount available under its existing debt facility.
 
Proceeds will be used to support the company’s anticipated commercial launch, further clinical trials, and expanding application development of its Edison histotripsy therapy platform throughout the body.
 

“These financings are an extraordinary vote of confidence in our team, as well as the novel platform and solution we have developed to transform experiences for patients and physicians who deal with the many challenges associated with significant disease, starting in the liver,” HistoSonics president and CEO Mike Blue told the press.
 
HistoSonics recently submitted safety and efficacy data from its #HOPE4LIVER clinical trials to the FDA and expects market authorization in 2023.
 
The company also appointed Silk Road Medical president and CEO Erica Rogers to its board of directors.
 
“I have been following HistoSonics’ progress for years and believe that histotripsy offers a unique non-invasive solution capable of addressing a variety of significant unmet clinical needs. I look forward to being a part of the HistoSonics team, helping to ensure the Edison platform reaches its full potential to treat patients with significant disease across global markets and a broad number of care settings,” commented Rogers.